Compare Agilysys Inc (AGYS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs Novavax Inc — how do they compare? Agilysys Inc trades at $107.52 (market cap $3.00B), while Novavax Inc trades at $7.92 (market cap $1.31B). The key difference: Agilysys Inc is far larger — about 2.3× Novavax Inc's market cap, and Agilysys Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| AGYS | NVAX | |
|---|---|---|
Market Cap | $3.00B | $1.31B |
Sector | Technology | Health |
52-Week High | $141.12 | $11.19 |
52-Week Low | $62.19 | $6.22 |
Enterprise Value | $2.90B | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $106.14, down 0.79% for the day, with a bullish technical signal from moving averages and a consensus analyst price target of $118.33. Recent Q1 2026 earnings beat expectations with EPS of $0.63 versus $0.4971, and the company raised its full-year outlook, driven by strong subscription revenue growth and deployment progress with key clients like Marriott.
The outlook is positive given robust earnings momentum and 100% buy ratings from analysts, though high valuation multiples (P/E of 70.01) and negative net cash flow in 2025 pose risks. Upside potential exists if subscription-led growth continues, but investors should monitor execution against elevated expectations.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
